Qin et al. reported that in ovarian cancer bardoxolone methyl acts as a selective inhibitor of deubiquitinating enzyme ubiquitin-specific protease 7 (USP7), which is known to be a critical regulator in the oncogenic processes of numerous malignancies. This evidence concerns the gene USP7 and ovarian carcinoma.